We speculated that comparing to the effects of PD-L1 expression, effects of EGFR-TKIs on the EGFR signaling pathway may be more dominating in the NSCLC molecular-targeted therapy response. This evidence concerns the gene CD274 and non-small cell lung carcinoma.